pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 42 Non-oncology: 28
Oncology: 14
Under Consideration for Negotiation 11 Non-oncology: 7
Oncology: 4
Completed Negotiations 816 With Letter of Intent: 708
Without agreement: 108
Negotiations That Were Not Pursued 110

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Lumakras Amgen Canada Inc. Advanced non-small cell lung cancer, KRAS G12C-mutated
Otulfi Fresenius Kabi Canada Ltd. Multiple Indications
Yesintek Biocon Biologics Canada Inc. Multiple Indications
Darzalex SC Janssen Inc. in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Avtozma Celltrion Healthcare Canada Ltd. Multiple Indications
Oslya Mantra Pharma Multiple Indications
Bildyos Organon Canada Inc. Multiple Indications
Bilprevda Organon Canada Inc. Multiple Indications
Obodence Samsung Bioepis Co., Ltd. Multiple Indications
Osdenza Apotex Inc. Osteoporosis
Idenos Apotex Inc. Multiple Indications
Symtuza Janssen Inc. HIV-1 Infection
Rystiggo UCB Canada Inc. Generalized myasthenia gravis (gMG)

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
Evkeeza Ultragenyx Pharmaceutical Inc. Homozygous Familial Hypercholesterolemia
Ultomiris Alexion Pharma GmbH Generalized myasthenia gravis (gMG)
Ultomiris Alexion Pharma GmbH Neuromyelitis optica spectrum disorder (NMOSD)
Fruzaqla Takeda Canada Inc. For the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemother
Vemlidy Gilead Sciences Canada Inc. chronic Hepatitis B virus
TheraSphere Y-90 Glass Micropheres Boston Scientific Corporation As selective internal radiation therapy (SIRT) for local tumor control of solitary tumors in patients with intermediate- or advanced-stage hepatocellular carcinoma (HCC), including those with recurrent or unresectable HCC. In addition to HCC
Keytruda Merck Canada Inc. For the treatment of adult patients with primary advanced or recurrent endometrial carcinoma, in combination with carboplatin and paclitaxel and then continued as monotherapy.
Vabysmo Hoffmann-La Roche Ltd. Retinal vein occlusion
Pexegra Jamp Pharma Corporation Febrile neutropenia in non-myeloid malignancies
Venclexta AbbVie Corporation In combination with Gazyva, for the treatment of patients with previously untreated chronic lymphocytic leukemia
Filra Jamp Pharma Corporation Multiple Indications
Gazyva Hoffmann-La Roche Ltd. In combination with Venclexta, for the treatment of patients with previously untreated chronic lymphocytic leukemia

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
Awiqli Novo Nordisk Canada Inc. Diabetes Mellitus, Type 2

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
Winlevi Sun Pharma Canada Inc. Acne Vulgaris